Literature DB >> 25365067

Successful early unmanipulated haploidentical transplantation with reduced-intensity conditioning for primary graft failure after cord blood transplantation in hematologic malignancy patients.

B L Tang1, X Y Zhu1, C C Zheng1, H L Liu1, L Q Geng1, X B Wang1, K Y Ding1, W Yao1, J Tong1, K D Song1, L Zhang1, P Qiang1, Z M Sun1.   

Abstract

Primary graft failure (pGF) is a frequent complication following cord blood transplantation (CBT). For those patients who will not experience autologous recovery, salvage transplantation should be performed as early as possible. However, standardized treatment protocols for pGF, such as the optimal stem cell source, preparative regimen and the ideal time for salvage transplantation, have yet to be determined. Therefore, we analyzed 17 hematologic malignancy patients who received unmanipulated haploidentical peripheral blood (PB) and BM transplantation with reduced-intensity conditioning (RIC) as a salvage therapy for pGF after CBT. The median interval between the two transplantations was 38 days. The RIC regimen for salvage transplantation consisted of fludarabine, antithymocyte globulin, CY and low-dose TBI. The neutrophil and plt engraftments were achieved in 14 (82.4%) and 13 (76.4%) patients, respectively. The cumulative incidences of grades II-IV and grades III-IV aGVHD were 35.3% and 17.6%, respectively. The cumulative incidence of chronic GVHD was 29.4%. After a median follow-up of 43 months, 10 of 17 patients remained alive in CR. The cumulative incidence of TRM at 180 days was 29.4%. The probability of 3-year OS and leukemia-free survival was 57.5%. Our results show that unmanipulated haploidentical PB and BM transplantation under a RIC regimen is an effective treatment for pGF after CBT.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25365067     DOI: 10.1038/bmt.2014.250

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  29 in total

1.  Regression modeling of competing risk using R: an in depth guide for clinicians.

Authors:  L Scrucca; A Santucci; F Aversa
Journal:  Bone Marrow Transplant       Date:  2010-01-11       Impact factor: 5.483

2.  Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide.

Authors:  L Luznik; S Jalla; L W Engstrom; R Iannone; E J Fuchs
Journal:  Blood       Date:  2001-12-01       Impact factor: 22.113

3.  Peripheral blood as a preferable source of stem cells for salvage transplantation in patients with graft failure after cord blood transplantation: a retrospective analysis of the registry data of the Japanese Society for Hematopoietic Cell Transplantation.

Authors:  Shigeo Fuji; Fumiaki Nakamura; Kazuo Hatanaka; Shuichi Taniguchi; Maho Sato; Shin-Ichiro Mori; Hisashi Sakamaki; Hiromasa Yabe; Toshihiro Miyamoto; Heiwa Kanamori; Yasunori Ueda; Keisei Kawa; Koji Kato; Ritsuro Suzuki; Yoshiko Atsuta; Toshiharu Tamaki; Yoshinobu Kanda
Journal:  Biol Blood Marrow Transplant       Date:  2012-03-16       Impact factor: 5.742

4.  Bloodstream infection after umbilical cord blood transplantation using reduced-intensity stem cell transplantation for adult patients.

Authors:  Hiroto Narimatsu; Tomoko Matsumura; Masahiro Kami; Shigesaburo Miyakoshi; Eiji Kusumi; Shinsuke Takagi; Yuji Miura; Daisuke Kato; Chiho Inokuchi; Tomohiro Myojo; Yukiko Kishi; Naoko Murashige; Koichiro Yuji; Kazuhiro Masuoka; Akiko Yoneyama; Atsushi Wake; Shinichi Morinaga; Yoshinobu Kanda; Shuichi Taniguchi
Journal:  Biol Blood Marrow Transplant       Date:  2005-06       Impact factor: 5.742

5.  Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia.

Authors:  Vanderson Rocha; Myriam Labopin; Guillermo Sanz; William Arcese; Rainer Schwerdtfeger; Alberto Bosi; Niels Jacobsen; Tapani Ruutu; Marcos de Lima; Jürgen Finke; Francesco Frassoni; Eliane Gluckman
Journal:  N Engl J Med       Date:  2004-11-25       Impact factor: 91.245

6.  Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation.

Authors:  Dao-Pei Lu; Lujia Dong; Tong Wu; Xiao-Jun Huang; Mei-Jie Zhang; Wei Han; Huan Chen; Dai-Hong Liu; Zhi-Yong Gao; Yu-Hong Chen; Lan-Ping Xu; Yao-Chen Zhang; Han-Yun Ren; Dan Li; Kai-Yan Liu
Journal:  Blood       Date:  2005-12-27       Impact factor: 22.113

7.  Salvage haploidentical transplantation for graft failure using reduced-intensity conditioning.

Authors:  S Yoshihara; K Ikegame; K Taniguchi; K Kaida; E H Kim; J Nakata; R Kato; T Inoue; T Fujioka; H Tamaki; M Okada; T Soma; H Ogawa
Journal:  Bone Marrow Transplant       Date:  2011-04-11       Impact factor: 5.483

8.  A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation.

Authors:  Fabio Ciceri; Myriam Labopin; Franco Aversa; Jakob M Rowe; Donald Bunjes; Philippe Lewalle; Arnon Nagler; Paolo Di Bartolomeo; João F Lacerda; Maria Teresa Lupo Stanghellini; Emmanuelle Polge; Francesco Frassoni; Massimo F Martelli; Vanderson Rocha
Journal:  Blood       Date:  2008-07-07       Impact factor: 22.113

9.  Booster marrow or blood cells for graft failure after allogeneic bone marrow transplantation.

Authors:  M Remberger; O Ringdén; P Ljungman; H Hägglund; J Winiarski; B Lönnqvist; J Aschan
Journal:  Bone Marrow Transplant       Date:  1998-07       Impact factor: 5.483

Review 10.  Umbilical cord blood transplantation: the first 20 years.

Authors:  John E Wagner; Eliane Gluckman
Journal:  Semin Hematol       Date:  2010-01       Impact factor: 3.851

View more
  4 in total

1.  Comparison of the outcomes after haploidentical and cord blood salvage transplantations for graft failure following allogeneic hematopoietic stem cell transplantation.

Authors:  Kaito Harada; Shigeo Fuji; Sachiko Seo; Junya Kanda; Toshimitsu Ueki; Fumihiko Kimura; Koji Kato; Naoyuki Uchida; Kazuhiro Ikegame; Makoto Onizuka; Ken-Ichi Matsuoka; Noriko Doki; Toshiro Kawakita; Yasushi Onishi; Shingo Yano; Takahiro Fukuda; Minoko Takanashi; Yoshinobu Kanda; Yoshiko Atsuta; Masao Ogata
Journal:  Bone Marrow Transplant       Date:  2020-02-12       Impact factor: 5.483

2.  Salvage HLA-haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide for graft failure in non-malignant disorders.

Authors:  Michael H Albert; Mehtap Sirin; Manfred Hoenig; Fabian Hauck; Catharina Schuetz; Rajat Bhattacharyya; Polina Stepensky; Elad Jacoby; Tayfun Güngör; Rita Beier; Ansgar Schulz
Journal:  Bone Marrow Transplant       Date:  2021-05-09       Impact factor: 5.483

3.  Graft Failure in Patients With Hematological Malignancies: A Successful Salvage With a Second Transplantation From a Different Haploidentical Donor.

Authors:  Yu-Qian Sun; Yu Wang; Feng-Rong Wang; Chen-Hua Yan; Yi-Fei Cheng; Yu-Hong Chen; Yuan-Yuan Zhang; Ting-Ting Han; Wei Han; Pan Suo; Lan-Ping Xu; Xiao-Hui Zhang; Kai-Yan Liu; Xiao-Jun Huang
Journal:  Front Med (Lausanne)       Date:  2021-06-04

4.  Haploidentical hematopoietic stem cell transplantation in a myelofibrosis patient with primary graft failure.

Authors:  Cristina Tecchio; Angelo Andreini; Claudio Costantini; Alberto Zamò; Donata de Sabata; Fiorenza Aprili; Roberta Galavotti; Emanuele Guardalben; Fabio Benedetti
Journal:  Hematol Rep       Date:  2018-01-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.